Dhiti Omics Technologies Profile
Key Indicators
- Authorised Capital ₹ 2.50 M
as on 10-12-2024
- Paid Up Capital ₹ 1.87 M
as on 10-12-2024
- Company Age 10 Year, 5 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 2.69 M
as on 10-12-2024
- Revenue 176.42%
(FY 2022)
- Profit 4.58%
(FY 2022)
- Ebitda 42.67%
(FY 2022)
- Net Worth -6.87%
(FY 2022)
- Total Assets 116.62%
(FY 2022)
About Dhiti Omics Technologies
The Company is engaged in the Life Sciences Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 2.50 M and a paid-up capital of Rs 1.87 M.
The company currently has active open charges totaling ₹2.69 M.
Ramesh Kannan, Sudha Rao, and Meena Vaidyanathan serve as directors at the Company.
- CIN/LLPIN
U24100KA2014PTC075038
- Company No.
075038
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
24 Jun 2014
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Bangalore
Industry
Company Details
- Location
Bangaluru, Karnataka, India
- Telephone
- Email Address
- Website
- Social Media
What products or services does Dhiti Omics Technologies Private Limited offer?
Dhiti Omics Technologies Private Limited offers a wide range of products and services, including Medical Treatment Services.
Who are the key members and board of directors at Dhiti Omics Technologies?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Sudha Rao  | Director | 24-Jun-2014 | Current |
| Ramesh Kannan | Director | 24-Jun-2014 | Current |
| Meena Vaidyanathan | Director | 02-Sep-2019 | Current |
Financial Performance and Corporate Structure Insights of Dhiti Omics Technologies.
Dhiti Omics Technologies Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 176.42% increase. The company also saw a slight improvement in profitability, with a 4.58% increase in profit. The company's net worth dipped by a decrease of 6.87%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Dhiti Omics Technologies?
In 2021, Dhiti Omics Technologies had a promoter holding of 62.78% and a public holding of 37.22%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Somerset Healthcare Investment Advisors Private LimitedActive 10 years 3 monthsRamesh Kannan is a mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Hdfc Bank Limited Creation Date: 19 Nov 2015 | ₹2.69 M | Open |
How Many Employees Work at Dhiti Omics Technologies?
Unlock and access historical data on people associated with Dhiti Omics Technologies, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Dhiti Omics Technologies, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Dhiti Omics Technologies's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
